Myriad Genetics Dirección

Dirección controles de criterios 2/4

El CEO de Myriad Genetics' es Paul Diaz , nombrado en Aug 2020, tiene una permanencia de 3.83 años. compensación anual total es $12.11M, compuesta por 9% salario y 91% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.38% de las acciones de la empresa, por valor de $7.97M. La antigüedad media del equipo directivo y de la junta directiva es de 2.4 años y 4.1 años, respectivamente.

Información clave

Paul Diaz

Chief Executive Officer (CEO)

US$12.1m

Compensación total

Porcentaje del salario del CEO	9.0%
Permanencia del CEO	3.8yrs
Participación del CEO	0.4%
Permanencia media de la dirección	2.4yrs
Promedio de permanencia en la Junta Directiva	4.3yrs

Actualizaciones recientes de la dirección

Recent updates

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?

Jun 05

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

May 11

Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

May 09

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Mar 28

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Feb 02

Myriad Genetics receives expanded coverage in Japan for breast cancer diagnostic system

Aug 25

Are Investors Undervaluing Myriad Genetics, Inc. (NASDAQ:MYGN) By 50%?

Aug 05

Myriad Genetics Q2 2022 Earnings Preview

Aug 03

Myriad Genetics touts study results of GeneSight test on depression remission rates

Jul 12

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Paul Diaz en comparación con los beneficios de Myriad Genetics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$235m
Dec 31 2023	US$12m	US$1m	-US$263m
Sep 30 2023	n/a	n/a	-US$274m
Jun 30 2023	n/a	n/a	-US$248m
Mar 31 2023	n/a	n/a	-US$146m
Dec 31 2022	US$11m	US$1m	-US$112m
Sep 30 2022	n/a	n/a	-US$77m
Jun 30 2022	n/a	n/a	-US$18m
Mar 31 2022	n/a	n/a	-US$8m
Dec 31 2021	US$13m	US$1m	-US$27m
Sep 30 2021	n/a	n/a	-US$57m
Jun 30 2021	n/a	n/a	-US$97m
Mar 31 2021	n/a	n/a	-US$148m
Dec 31 2020	US$16m	US$383k	-US$224m

Compensación vs. Mercado: La compensación total de Paul($USD12.11M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD5.64M).

Compensación vs. Ingresos: La compensación de Paul ha aumentado mientras la empresa no es rentable.

CEO

Paul Diaz (62 yo)

3.8yrs

Permanencia

US$12,108,359

Compensación

Mr. Paul J. Diaz serves as the Member of Advisory Board at Thornton Capital, LLC. He has been the Chief Executive Officer, President and Director of Myriad Genetics, Inc. since August 13, 2020. He serves a...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul Diaz	CEO, President & Director	3.8yrs	US$12.11m	0.38% $ 8.4m
Samraat Raha	Chief Operating Officer	less than a year	US$5.02m	sin datos
Dale Muzzey	Chief Scientific Officer	2.4yrs	US$2.23m	0.12% $ 2.7m
Mark Verratti	Chief Commercial Officer	6.8yrs	US$2.88m	0.33% $ 7.4m
Scott Leffler	Chief Financial Officer	less than a year	sin datos	sin datos
Natalie Munk	Principal Accounting Officer	2yrs	sin datos	0.049% $ 1.1m
Kevin Haas	Chief Technology Officer	3.3yrs	US$1.64m	0.15% $ 3.3m
Matthew Scalo	Senior Vice President of Investor Relations	no data	sin datos	sin datos
Justin Hunter	Interim General Counsel & Corporate Secretary	3.3yrs	sin datos	sin datos
Glenn Farrell	Senior VP & Chief Marketing Officer	1.5yrs	sin datos	sin datos
Shereen Solaiman	Chief People Officer	1.3yrs	sin datos	0.0032% $ 70.5k
Patrick Burke	Executive Vice President of Strategy & Innovation	3.1yrs	sin datos	sin datos

2.4yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MYGN se considera experimentado (2.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Paul Diaz	CEO, President & Director	3.8yrs	US$12.11m	0.38% $ 8.4m
Paul Bisaro	Independent Director	1.7yrs	US$258.48k	0.027% $ 602.8k
Lee Newcomer	Independent Director	4.8yrs	US$447.99k	0.074% $ 1.6m
Daniel Skovronsky	Independent Director	3.9yrs	US$433.49k	0.078% $ 1.7m
Colleen Reitan	Independent Director	4.8yrs	US$443.49k	0.080% $ 1.8m
Heinrich Dreismann	Independent Director	14yrs	US$443.49k	0.13% $ 2.9m
S. Phanstiel	Independent Chair of the Board	14.8yrs	US$563.49k	0.16% $ 3.6m
Rashmi Kumar	Independent Director	3.8yrs	US$433.49k	0.076% $ 1.7m

4.3yrs

Permanencia media

63.5yo

Promedio de edad

Junta con experiencia: La junta directiva de MYGN se considera experimentada (4.1 años de antigüedad promedio).

Myriad Genetics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

CEO, President & Director recently sold US$5.7m worth of stock

CEO, President & Director notifies of intention to sell stock

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Executive VP notifies of intention to sell stock

Myriad Genetics, Inc. Appoints Samraat S. Raha as Chief Operating Officer, Effective as of December 11, 2023

Recent updates

Is Myriad Genetics, Inc. (NASDAQ:MYGN) Trading At A 33% Discount?

CEO, President & Director recently sold US$5.7m worth of stock

CEO, President & Director notifies of intention to sell stock

Myriad Genetics, Inc.'s (NASDAQ:MYGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report

Myriad Genetics, Inc. Reiterates Earnings Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Myriad Genetics, Inc. to Report Q1, 2024 Results on May 07, 2024

Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?

Consensus EPS estimates upgraded to US$0.93 loss

Price target increased by 8.9% to US$24.50

Myriad Genetics, Inc. Provides Revenue Guidance for the First Quarter 2024

Full year 2023 earnings: EPS misses analyst expectations

Myriad Genetics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued

Myriad Genetics' Strategic Growth Fuels Bullish Outlook

Myriad Genetics, Inc. Appoints George Daneker as President and Chief Clinical Officer of Oncology, Effective March 18, 2024

Myriad Genetics, Inc. (NasdaqGS:MYGN) agreed to acquire Select assets of Intermountain Precision Genomics.

Myriad Genetics, Inc. Announces Chief Financial Officer Changes

Revenues Working Against Myriad Genetics, Inc.'s (NASDAQ:MYGN) Share Price

Consensus EPS estimates fall by 21%, revenue upgraded

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New minor risk - Shareholder dilution

Myriad Genetics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Myriad Genetics, Inc. Provides Financial Guidance for 2023 and 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Executive VP notifies of intention to sell stock

Myriad Genetics, Inc. Appoints Samraat S. Raha as Chief Operating Officer, Effective as of December 11, 2023

Myriad Genetics Appoints Sam Raha as Chief Operating Officer, Effective December 11, 2023

Myriad Genetics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Price target decreased by 8.2% to US$21.67

Bernstein Litowitz Berger & Grossmann LLP Proposes Settlement of Class Action Involving Persons Who Purchased or Acquired Myriad Genetics, Inc. Common Stock

Insufficient new directors

Consensus EPS estimates fall by 52%

Myriad Genetics Announces Enhancements to the Genesight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

Is Myriad Genetics (NASDAQ:MYGN) Using Debt Sensibly?

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Myriad Genetics, Inc. Provides Earnings Guidance for the Year 2023

Myriad Genetics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Myriad Genetics, Inc. Announces Inclusion of Breast Density to Myrisk(R) with Riskscore(R) Breast Cancer Risk Assessment

Independent Director notifies of intention to sell stock

Myriad Genetics, Inc. Appoints Adam Brufsky as Scientific Advisor

Consensus EPS estimates fall by 27%, revenue upgraded

Myriad Genetics, Inc. Revises Earnings Guidance for the Full Year of 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 7.7% to US$21.72

Calculating The Intrinsic Value Of Myriad Genetics, Inc. (NASDAQ:MYGN)

Chief Operating Officer notifies of intention to sell stock

Chief Operating Officer notifies of intention to sell stock

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 24%

Executive VP notifies of intention to sell stock

Myriad Genetics, Inc. Hires Senior Leaders to Advance Commercial Growth Plans

Myriad Genetics, Inc. announces Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

High number of new directors

Price target decreased to US$20.44

Myriad Genetics Announces Urosuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-Driven Medical Information

Consensus EPS estimates fall by 103%

Price target decreased to US$22.19

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Myriad Genetics, Inc. (NasdaqGS:MYGN) acquired Gateway Genomics, LLC for approximately $110 million.

Myriad Genetics, Inc. Elects Paul M. Bisaro as New Board Member

High number of new directors

Myriad Genetics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Myriad: Trying To Find Its Footing In An Evolving Industry

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

Myriad Genetics receives expanded coverage in Japan for breast cancer diagnostic system

Price target increased to US$24.36

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind